CVG Stock Overview
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
CSPC Pharmaceutical Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.63 |
| 52 Week High | HK$0.95 |
| 52 Week Low | HK$0.51 |
| Beta | 0.64 |
| 11 Month Change | -16.71% |
| 3 Month Change | 15.93% |
| 1 Year Change | -21.95% |
| 33 Year Change | -34.93% |
| 5 Year Change | -46.77% |
| Change since IPO | 1,101.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| CVG | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 2.2% | -5.0% | -1.3% |
| 1Y | -21.9% | -22.0% | 7.4% |
Return vs Industry: CVG matched the German Pharmaceuticals industry which returned -21.6% over the past year.
Return vs Market: CVG underperformed the German Market which returned 7.1% over the past year.
Price Volatility
| CVG volatility | |
|---|---|
| CVG Average Weekly Movement | 12.2% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CVG's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: CVG's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 20,300 | Cuilong Zhang | www.cspc.com.hk |
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson’s disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer.
CSPC Pharmaceutical Group Limited Fundamentals Summary
| CVG fundamental statistics | |
|---|---|
| Market cap | €7.41b |
| Earnings (TTM) | €679.70m |
| Revenue (TTM) | €3.99b |
10.9x
P/E Ratio1.9x
P/S RatioIs CVG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CVG income statement (TTM) | |
|---|---|
| Revenue | CN¥30.27b |
| Cost of Revenue | CN¥8.90b |
| Gross Profit | CN¥21.37b |
| Other Expenses | CN¥16.21b |
| Earnings | CN¥5.16b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.44 |
| Gross Margin | 70.59% |
| Net Profit Margin | 17.04% |
| Debt/Equity Ratio | 1.1% |
How did CVG perform over the long term?
See historical performance and comparison